Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 2/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29430899 | 1.00 | ALDH1A1 (0.50) | ALDH1A1KDM4EPKMHPGDHSD17B10 | |
| SCHEMBL8217686 | 0.83 | ALDH1A1 (0.45) | ALDH1A1KDM4EPKMHPGDHSD17B10 | |
| SCHEMBL40549 | 0.82 | ALDH1A1 (0.46) | ALDH1A1KDM4EPKMHPGDHSD17B10 | |
| SCHEMBL29449219 | 0.82 | ALDH1A1 (0.46) | ALDH1A1KDM4EPKMHPGDHSD17B10 | |
| Hydrochloric Acid SCHEMBL11772004 | 0.80 | ALDH1A1 (0.44) | ALDH1A1KDM4EPKMHPGDHSD17B10 | |
| SCHEMBL29637726 | 0.78 | PTPN5 (0.41) | ALDH1A1PKMMAPTMEN1KMT2A | |
| SCHEMBL7863398 | 0.78 | PTPN5 (0.41) | ALDH1A1PKMMAPTMEN1KMT2A | |
| SCHEMBL29505675 | 0.78 | ALDH1A1 (0.55) | ALDH1A1KDM4EPKMHPGDHSD17B10 | |
| SCHEMBL161784 | 0.78 | ALDH1A1 (0.55) | ALDH1A1KDM4EPKMHPGDHSD17B10 | |
| SCHEMBL14918987 | 0.77 | ALDH1A1 (0.57) | ALDH1A1PKMHPGDHSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 438 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005100434-A1 | HALOGEN CONTAINING EPOXY COMPOSITIONS AND THEIR PREPARATION | UNIVERSITY OF NORTH TEXAS (US) | 2005-10-27 | — | — | WO | claimed |
| US-20050228080-A1 | Halogen containing epoxy compositions and their preparation | UNIVERSITY OF NORTH TEXAS (US) | 2005-10-13 | — | — | US | claimed |
| US-5354495-A | Homo- or copolymerizable through ethylenic unsaturation | NIPPON PAINT CO., LTD. (JP) | 1994-10-11 | — | — | US | claimed |
| EP-0177122-B1 | ACRYLAMIDE DERIVATIVES | Nippon Paint Co., Ltd. (JP) | 1992-04-01 | — | — | EP | claimed |
| US-4935413-A | ELASTICITY, ADHESION AND DISPERSIBILITY | NIPPON PAINT CO., LTD. (JP) | 1990-06-19 | — | — | US | claimed |
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | GENENTECH, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| EP-3601235-B1 | BICYCLIC HETEROARYL DERIVATIVES, PREPARATION AND THERAPEUTIC USES THEREOF | XWPHARMA LTD (KY) | 2026-03-04 | — | — | EP | disclosed |
| EP-4153170-B1 | MAXI-K POTASSIUM CHANNEL OPENERS FOR THE TREATMENT OF FRAGILE X ASSOCIATED DISORDERS | SERVIER LAB (FR) | 2026-01-21 | — | — | EP | disclosed |
| EP-4655287-A2 | INHIBITORS OF NLRP3 | MWYNGIL THERAPEUTICS, INC. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12377084-B2 | ERAP1 modulators | Grey Wolf Therapeutics Limited (GB) | 2025-08-05 | — | — | US | disclosed |
| US-20250084094-A1 | SPIROCYCLIC INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2025-03-13 | — | — | US | disclosed |
| WO-2025049746-A1 | COMPOSITIONS COMPRISING WERNER SYNDROME HELICASE INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-4493800-A | REACTING A TRIFLUOROMETHYLHALOGENOBENZENE WITH COPPER CYANIDE | DAIKIN KOGYO CO., LTD. (JP) | 1985-01-15 | — | — | US | disclosed |
| EP-0097357-A1 | Process for preparing trifluoromethylbenzene derivatives | Daikin Kogyo Co., Ltd. (JP) | 1984-01-04 | — | — | EP | disclosed |
| US-4209464-A | Novel synthesis of 3-amino-2-methylbenzotrifluoride from N-(2-X-5-trifluoromethylphenyl)-S,S-dimethylsulfimide | SCHERING CORPORATION (US) | 1980-06-24 | — | — | US | disclosed |
| US-4172095-A | Novel synthesis of 3-amino-2-methylbenzotrifluoride and the intermediates thereof | SCHERING CORPORATION (US) | 1979-10-23 | — | — | US | disclosed |
| US-4062846-A | CNS STIMULANTS, MUSCLE RELAXANT | E. R. SQUIBB & SONS, INC. (US) | 1977-12-13 | — | — | US | disclosed |
| US-4051121-A | Azo pigments having two 2-halo-5-trifluoromethylphenyl diazo component radicals and a bis-(2-hydroxynaphthoyl-3-amino)-2,5-dihalobenzene coupling component radical | SANDOZ LTD. (CH) | 1977-09-27 | — | — | US | disclosed |
| US-RE28939-E | MUSCLE RELAXANTS, ANALGESICS | SMITHKLINE CORPORATION (US) | 1976-08-24 | — | — | US | disclosed |
| US-3966733-A | CENTRAL NERVOUS SYSTEM STIMULANTS, MUSCLE RELAXANTS | E. R. SQUIBB & SONS, INC. (US) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12377084-B2 | ERAP1 modulators | ERAP1, NR1I3, HRH4 | ALDH1A1 2660/4885KDM4E 737/4885PKM 4349/4885 |
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | NLRP3, NLRP1, PYCARD | ALDH1A1 2022/4885KDM4E 4052/4885PKM 1724/4885 |
| US-20250084094-A1 | SPIROCYCLIC INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, PNLIP, FMNL1 | ALDH1A1 2430/4885KDM4E 4825/4885PKM 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.